Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that ...

Prostate cancer affects one in eight men during their lifetime, making it the second most common cancer among American males.

Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...

In a groundbreaking clinical trial, immunotherapy alone eliminated rectal cancer in all 14 participants. This study, the ...

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies ...

One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients with FGFR2/3 mutations. With the growing emphasis on ...

Keven Williams says a private health check-up did not detect his cancer. By the time he was diagnosed two years later, it had ...

First patient enrolled in the Phase II panSOHO basket trial; this is the third BAY 2927088 clinical trial in patients with HER2- activating mutations ...

Discover a study that found that the combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...